Targets › LCAT
1 program from 1 company in 1 trial: 1 Phase 3; Neurology.
Central enzyme in the extracellular metabolism of plasma lipoproteins. Synthesized mainly in the liver and secreted into plasma where it converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines on the surface of high and low density lipoproteins (HDLs and LDLs). (UniProt, P04180)
Open in Phaseline: the race on LCAT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ScandiBio Therapeutics | CMA2 Combined metabolic activator containing N-acetyl-L-cysteine, L-carnitine-L-tartrate, nicot | NAC, LCAT, NICOTINAMIDE, L-SERINE | Phase 3 | Alzheimer Disease | – |
Alzheimer Disease (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.